Variables | N(%) | The overall survival rate | Univariate analysis |
---|---|---|---|
Age | Â | Â | 0.086 |
 31–59 | 37(41.6) | 43.2 | |
 60–87 | 52(58.4) | 34.6 | |
Gender | Â | Â | 0.500 |
 Male | 54(60.7) | 37.0 | |
 Female | 35(39.3) | 40.0 | |
Histories of smoking and alcohol | Â | Â | 0.867 |
 Yes | 49(55.1) | 55.1 | |
 No | 40(44.9) | 35.0 | |
Premalignant mucosal diseases | Â | Â | 0.257 |
 Yes | 27(30.3) | 30.3 | |
 No | 62(69.7) | 35.5 | |
Prior radio- or chemo-therapies | Â | Â | 0.011 |
 Yes | 22(24.7) | 24.7 | |
 No | 67(75.3) | 43.3 | |
Treatment status | Â | Â | < 0.001 |
 Primary lesions for treatment (PG) | 25(28.1) | 56.0 | |
 Staged (secondary) neck dissections (SG) | 28(31.5) | 53.6 | |
 Recurrent or residual lesions for salvage surgery (RRG) | 36(43.8) | 13.9 | |
Primary or recurrent site | Â | Â | 0.005 |
 Buccal mucosa | 7(7.9) | 42.9 | |
 Upper gingiva | 13(14.6) | 30.8 | |
 Lower gingiva | 12(13.5) | 41.7 | |
 Floor of mouth | 5(5.6) | 20.0 | |
 Tongue | 24(27.0) | 37.5 | |
 Retromolar trigone | 9(10.1) | 0.0 | |
 Lip | 6(6.7) | 83.3 | |
 Hard palate | 13(14.6) | 53.8 | |
Unconventional metastatic subsites | Â | Â | 0.008 |
 Buccinator | 45(50.6) | 44.4 | |
 Sublingual | 31(34.8) | 38.7 | |
 Parotida | 13(14.6) | 15.4 | |
Pathological grade | Â | Â | 0.002 |
 I | 4(4.5) | 50.0 | |
 II | 55(61.8) | 49.1 | |
 III | 30(33.7) | 16.7 | |
Number of metastatic lymph nodes in the unconventional subsites | Â | 0.087 | |
 1 | 68(76.4) | 42.6 | |
 2 | 20(22.5) | 25.0 | |
 3 | 1(1.1) | 0.0 | |
Lymph nodes size of UMLNs | Â | Â | 0.003 |
 0–3 cm | 65(73.0) | 44.6 | |
 > 3 cm | 24(27.0) | 20.8 | |
Extranodal extension (ENE) in UMLNs | Â | Â | < 0.001 |
 Yes | 28(31.5) | 17.9 | |
 No | 61(68.5) | 47.5 | |
Contralateral metastasis | Â | Â | < 0.001 |
 Yes | 27(30.3) | 30.3 | |
 No | 62(69.7) | 50.0 | |
Concurrent with cervical lymph node metastases | Â | Â | 0.003 |
 Yes | 58(65.2) | 65.2 | |
 No | 31(34.8) | 64.5 | |
Extranodal extension (ENE) in cervical lymph nodes | Â | Â | < 0.001 |
 Yes | 21(23.6) | 23.6 | |
 No | 68(76.4) | 48.5 | |
Neck dissection | Â | Â | < 0.001 |
 ISND | 18(20.2) | 61.1 | |
 IRND | 31(34.8) | 54.8 | |
 CND | 8(9.0) | 0.0 | |
 BND | 25(28.1) | 12.0 | |
 None | 7(7.9) | 42.9 | |
Anti-EGFR therapy | Â | Â | 0.957 |
 Yes | 16(18.0) | 31.3 | |
 No | 73(82.0) | 39.7 | |
Postoperative adjuvant therapies | Â | Â | 0.042 |
 Radiotherapy | 41(46.1) | 46.3 | |
 Chemotherapy | 3(3.4) | 0.0 | |
 Radio-chemotherapies | 25(28.1) | 32.0 | |
 None | 20(22.5) | 35.0 |